FY2019 Earnings Estimate for Synthetic Biologics, Inc. Issued By William Blair (SYN)
Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) – Equities research analysts at William Blair decreased their FY2019 earnings per share estimates for shares of Synthetic Biologics in a note issued to investors on Monday, April 23rd. William Blair analyst Y. Xu now expects that the company will earn $0.02 per share for the year, down from their prior estimate of $0.04.
Synthetic Biologics (NYSEAMERICAN:SYN) last announced its earnings results on Thursday, February 22nd. The company reported $0.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.07.
Shares of NYSEAMERICAN SYN opened at $0.23 on Thursday. Synthetic Biologics has a 1 year low of $0.19 and a 1 year high of $1.05.
A number of large investors have recently bought and sold shares of the stock. 683 Capital Management LLC acquired a new position in Synthetic Biologics in the fourth quarter worth about $762,000. Citadel Advisors LLC grew its stake in Synthetic Biologics by 312.1% in the fourth quarter. Citadel Advisors LLC now owns 241,797 shares of the company’s stock worth $122,000 after purchasing an additional 183,120 shares in the last quarter. Finally, Virtu Financial LLC grew its stake in Synthetic Biologics by 256.1% in the fourth quarter. Virtu Financial LLC now owns 299,577 shares of the company’s stock worth $152,000 after purchasing an additional 215,440 shares in the last quarter.
About Synthetic Biologics
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.